Quick Answer
DiaMedica Therapeutics Inc. reported Cash and Equivalents of $15.65 million for fiscal year 2025.
DiaMedica Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.65M | +417.3% |
| 2024 | $3.02M | -33.4% |
| 2023 | $4.54M | -3.9% |
| 2022 | $4.73M | +0.4% |
| 2021 | $4.71M | -36.5% |
| 2020 | $7.41M | +90.8% |
| 2019 | $3.88M | -76.9% |
| 2018 | $16.82M | +1143.4% |
| 2017 | $1.35M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.33M | -19.5% | -19.1% |
| June 30, 2025 | $4.11M | -70.8% | +58.7% |
| March 31, 2025 | $2.59M | +23.5% | -14.4% |
| December 31, 2024 | $3.02M | -33.4% | -26.8% |
| September 30, 2024 | $4.13M | +85.2% | -70.6% |
| June 30, 2024 | $14.07M | +140.9% | +570.8% |
| March 31, 2024 | $2.10M | -2.3% | -53.8% |
| December 31, 2023 | $4.54M | -3.9% | +103.5% |
- DiaMedica Therapeutics Inc. showed an increase of +417.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, DiaMedica Therapeutics Inc.’s cash and equivalents has grown by 1056.5% (from $1.35 million to $15.65 million).
- The most recent figure is from DiaMedica Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: